Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in ...

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

Pembrolizumab is an immune checkpoint inhibitor used in many ... the patient was started on prednisone 1 mg/kg daily with a plan for the continuation of systemic steroids for 4–6 weeks pending ...

“The combination of NC410 and pembrolizumab continues to demonstrate clinical activity against ovarian cancer and MSS/MSI-L CRC, recalcitrant cancers that are generally unresponsive to immunotherap ...

5.82 months with pembrolizumab in 1L PD-L1 positive advanced NSCLC. ITT Stratified HR: Ivonescimab significantly reduced the risk of disease progression or death by 49% vs. pembrolizumab ...

Online pharmacy startup Tata 1Mg has become the country’s 107th unicorn after raising close to $40 Mn in a funding round led by Tata Digital. The other participants in the round were KWE ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...